Personalized immune cells take aim at Drug-Resistant eye virus

NCT ID NCT07679412

Recruiting now Disease control Sponsor: LucasBio Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a new treatment called LB-DTK-CMV for people with cytomegalovirus (CMV) retinitis that has not responded to standard antiviral medicines. The treatment uses a patient's own immune cells, specially trained to attack CMV, and is given as two infusions. The trial aims to see if this approach is safe and can reduce the virus in the eye and blood, as well as improve vision-related symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LB-DTK-CMV (a personalized T-cell therapy made from the patient's own immune cells)

What this could lead to

If it works, this could offer a new treatment option for people with CMV retinitis that does not respond to standard antiviral drugs.

What could go wrong

This is a very early, small study with only 5 participants, so results may not apply to everyone. The therapy involves infusions that could cause side effects or fail to control the infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates